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Abstract:  The  p27  protein  is  a  canonical  negative  regulator  of  cell
proliferation and acts primarily by inhibiting cyclin-dependent kinases (CDKs).
Under  some  circumstances  p27  is  associated  with  active  CDK4,  but  no
mechanism  for  activation  has  been  described.  We  found  that  p27,  when
phosphorylated  by  tyrosine  kinases,  allosterically  activated  CDK4-CycD1.
Structural and biochemical data revealed that binding of phosphorylated p27
(phosp27) to CDK4 altered the kinase ATP site to promote phosphorylation of
the  retinoblastoma  tumor  suppressor  protein  (Rb)  and  other  substrates.
Surprisingly, purified and endogenous phosp27-CDK4-CycD1 complexes were
insensitive  to  the  CDK4-targeting  drug  palbociclib.  Palbociclib  instead
primarily targeted monomeric CDK4 and CDK6 (CDK4/6) in breast tumor cells.
Our data characterize phosp27-CDK4-CycD1 as an active Rb kinase that is
refractory to clinically relevant CDK4/6 inhibitors. 
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One Sentence Summary:  A kinase inhibitor and cancer drug works by an
unexpected mechanism.
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Main  Text: Cyclin-dependent  kinases  4  and  6  (CDK4/6)  drive  cell
proliferation by partnering with D-type cyclins (CycD) to phosphorylate the
retinoblastoma  protein  (Rb).  Rb  is  subsequently  hyperphosphorylated  and
inactivated by CDK2 to trigger passage through G1 phase of the cell cycle (1-
3).  Disruption of this CDK4/6–Rb signaling pathway is ubiquitous in tumors
and typically occurs through overexpression of CycD1 or loss of the CDK4/6
specific inhibitor p16INK4a, both of which increase CDK4/6 activity, leading to
uncontrolled  proliferation  (4-6).  Specific  CDK4/6-targeting  ATP-competitive
drugs such as palbociclib are approved for estrogen receptor–positive breast
cancer and are being tested in clinical trials for application in diverse cancer
types  (4, 5, 7, 8). As the use of CDK4/6 inhibitors as therapies increases, it
becomes critical  to understand their  mechanism and factors  that promote
sensitivity or resistance. 
CDK4/6  regulation  is  multilayered,  reflecting  the  need  to  integrate
diverse growth signals to control the cell cycle  (3). Canonical CDKs require
cyclin  binding  to  properly  structure  their  catalytic  site  (9).  CDK4-CycD  is
unique in that CycD binding alone does not induce an active kinase structure
(10, 11). CDK4-CycD also has relatively fewer characterized substrates and
poorer catalytic activity compared to other CDKs  (12-16). There are several
cofactors  that  interact  with  CDK4-CycD  to  modulate  complex  activity,
assembly  and  localization.  The  Rb  family  members  (Rb,  p107  and  p130),
which  are  the  best-characterized  substrates  of  CDK4,  contain  a  specific
activating  interaction  sequence  (15,  17,  18).  The  Hsp90-Cdc37  chaperone
complex stabilizes monomeric CDK4 by binding the unfolded N-lobe of the
kinase (19, 20).  The INK4 family (p19, p18, p16 and p15) inhibits CDK4/6 by
obstructing cyclin binding and by pulling the activation segment (also called
the  T-loop)  into  an  inactive  conformation  (21,  22).  Activation  segment
phosphorylation by the CDK-activating kinase (CAK) stimulates CDK4 activity
(23, 24).
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CIP (p21) and KIP (p27 and p57) proteins are CDK2 inhibitors  in vitro
and in  cells  under  conditions  of  growth  arrest  (25).  They  are  intrinsically
disordered proteins that fold onto a cyclin and then a CDK sequentially to
form ternary complexes  (26).   Mice lacking p21 or p27 are susceptible to
tumorigenesis (27, 28), which is consistent with the important roles of CIP and
KIP proteins in negatively regulating the cell cycle through CDK2 inhibition.
p27 degradation is critical for licensing entry into S phase, and p21 is a key
effector  of  p53-activated senescence  (25,  29).  p27 directly  inhibits  CDK2-
CycA by occluding a substrate-docking site and by inserting a small  helix
within the p27 CDK-inhibitory domain into the CDK2 ATP site (30).   
p21 and p27 have a more complex role in regulating CDK4. Although
they can inhibit  CDK4 under some conditions,  they are also necessary for
CDK4  activity.  Embryonic  fibroblasts  that  lack  both  p21  and  p27  fail  to
assemble  active  CDK4-CycD  complexes  (31).  Much  of  p27  is  found  in  a
complex with CDK4-CycD in proliferating cells, and active CDK4 complexes in
cells contain both CycD and p27  (25, 32-36).  While high levels of p21 are
inhibitory,  low  levels  induce  assembly  and  nuclear  localization  of
enzymatically active CDK4 complexes  (37). The activity of CDK4 complexes
requires  phosphorylation  of  p27 by  non-receptor  tyrosine  kinases  (NRTKs)
(34,  35,  38),  including  the  breast  tumor  kinase  Brk  (also  called  PTK6).
However, it is unclear whether and how p21 and p27 directly stimulate CDK4
catalytic activity, how this activation is mediated by p27 phosphorylation, and
how  p27  influences  CDK4’s  sensitivity  to  chemical  inhibitors  such  as
palbociclib.
Crystal  structures  of  p21-CDK4-CycD1  and  p27-CDK4-CycD1
complexes
To better understand p21 and p27 regulation of CDK4, we determined the
crystal structures of p21-CDK4-CycD1 and p27-CDK4-CycD1 complexes at 3.2
Å and 2.3 Å resolution, respectively (Fig. 1 and Tables S1 and S2). p21 and
p27 similarly fold into a single helix that spans CDK4-CycD1. The structures
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demonstrate why both proteins function as assembly factors. p21 and p27
contain a subdomain 1 (D1), which docks into a hydrophobic cleft in CycD1,
and a subdomain 2 (D2), which binds the N-lobe of CDK4 (Fig. 1 and Fig. 2).
CDK4 and CycD1 are joined through the bridging helix (α1), which provides a
rigid constraint to define the relative orientation of the cyclin and kinase N-
lobe domains (Fig. 1, A and B). 
The trimer structures demonstrate two key mechanisms of inhibition. First,
p21 and p27 use their RxLF motif in D1 to block access to a critical substrate-
docking site on CycD (Fig. 2, A and B) (39, 40). Similar D1 domain-mediated
interactions are also observed between p27 and CDK2-CycA (Fig. S1, A and
B). In a second inhibitory mechanism, the p21 and p27 D2 domains displace
the first strand (1) of the CDK4 N-lobe β-sheet (Fig. 2C). As a result, the
glycine rich loop (Gly-loop;  residues 13-19 in CDK4) is  dislodged from the
CDK4 active site and the ATP-binding pocket is disrupted. A striking difference
in how p27 binds CDK2 and CDK4 was observed in the interaction between
p27 D2 and the kinase domain. Whereas p27 inserts a small 310-helix into the
CDK2  ATP  site  (30),  a  310-helix  was  not  observed  at  the  corresponding
location in CDK4 (Fig. 2D and Fig. S1C).  Differences in  the CDK4 hinge
region from CDK2 suggest that 310-helix insertion of p27 into the CDK4 active
site would be sterically hindered (Fig. S1D). 
p21  and  p27  binding  rotates  the  CDK4  N-lobe  and  releases  the
kinase activation segment
We  compared  the  trimer  structures  to  the  known  CDK4-CycD  dimer
structures  (10, 11). Unexpectedly, p21 and p27 induced structural changes
that better shape the active site for catalysis. p27 binding rotated the N-lobe
of CDK4 toward CycD1 (Fig. 3, A through D). The strands in the N-lobe β-
sheet were shifted by ~4-6 Å such that β-strand 2 (β2) of the trimer complex
replaced the β-strand 3 (β3) position of the dimer, β3 replaced β5, and β5
replaced β4. An important consequence of this altered N-lobe conformation is
that the activation segment was released from the CDK4 active site, because
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specific interactions  between β3 and β5 and the activation  segment helix
were broken (Fig. 3B). The release represents an important step that allows
substrate  binding  in  the  kinase  active  site  (41).  For  CDK1  and  CDK2,
activation  segment  release  occurs  upon  binding  to  a  cognate  cyclin,  and
phosphorylation of the activation segment by CAK further improves substrate
binding (42). However, in the crystal structure of the CDK4-CycD1 dimer, the
activation segment remains in a substrate-blocking conformation despite the
introduction of a phosphomimetic (T172D) at the CAK phosphorylation site
(Fig. 3B)  (10).  The release of  the activation segment observed upon p27
binding (Fig. 3B)  is  a unique mechanism to CDK4 and likely  explains the
requirement  of  p27  for  CDK4 activation  segment  phosphorylation  by  CAK
(24).
A second result of the β-sheet rearrangement was that the catalytic lysine
(K35) on β3 was pulled into a position to accept the β- and γ- phosphates of
ATP  (Fig.  3,  C  and  D).  This  position  of  K35  is  similar  to  that  of  the
corresponding catalytic lysine (K33) in active CDK2-CycA (Fig. S1E) (9, 30).
In  contrast,  the position  of  K35 in  the CDK4-CycD1 dimer is  similar  to its
position in the inactive CDK2 monomer structure (10, 11). This conformational
change in the N-lobe does not occur when p27 binds CDK2 and is therefore an
allosteric activating mechanism of p27 specific to CDK4 (Fig. S1, A and F)
(30). 
While the p21 and p27 trimer complexes are primed for catalysis in that
K35 is positioned to coordinate ATP and the activation segment is released,
there  are  still  aspects  of  the  structure  that  indicate  additional  activating
mechanisms  are  required.  The  D2  domain  must  be  displaced  to  permit
formation  of  the ATP-binding  G-loop.  In  addition,  comparison  of  the  CDK4
trimer structure with an active CDK2 structure indicates that the C-helix (also
known as the PSTAIRE helix) in CDK4 remains in an inactive position, with its
critical catalytic glutamate pointing away from the active site (Fig. 2C and
Fig. 3D). We propose that the structure determined here is an intermediate
along a pathway to activation and that substrate binding,  ATP binding,  or
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activation  segment  phosphorylation  in  conjunction  with  p27  binding  may
induce the required rotation of the C-helix (Fig. S2A). 
Tyrosine phosphorylation of p27 but not p21 activates CDK4 trimer
complexes 
To  quantify  the  kinase  activity  of  p21-  and  p27-CDK4-CycD1,  we
assayed activity of recombinant CDK4 complexes (Fig. 3, E through G). We
used a phosphorylation site mimetic in the CDK4 activation segment (CDK4
T172E), because there was heterogeneity in phosphorylation of the T172 site
in our purified protein (Fig. S2, B and C).  We tested the CDK4-CycD1 dimer
(called  K4D1/-,  because it  lacks  p21 or  p27),  the  trimer  with  p21 or  p27
(K4D1/p21  or  K4D1/p27),  and  the  trimer  with  tyrosine  kinase  (Brk/PTK6)
phosphorylated p21 and p27 (K4D1/phosp21 or K4D1/phosp27) (Fig. 3E and
Fig. S3).  The dimer demonstrated strong activity toward the purified Rb C-
terminal  domain  (residues  771-928,  Rb771-928),  whereas  the  trimer  with
unphosphorylated p21 or unphosphorylated p27 demonstrated poor activity.
Consistent with observations in cell culture (34, 35), tyrosine phosphorylation
of p27 restored its recombinant trimer enzyme activity. The tyrosine kinase
phosphorylated p21 had only  slight  additional  activity,  indicating that p21
trimer complexes are mostly inhibited despite tyrosine phosphorylation. 
We focused on the strong activity of the phosphorylated p27 trimer and
used steady-state kinetic experiments to quantify enzyme processing of ATP
(Fig. 3, F and G, and Fig. S4). We tested CDK4 activity of the dimer and
the phosp27-trimer complex toward Rb771-928, Rb771-874 [residues 771-784; this
shorter Rb fragment lacks a CDK4 docking sequence (15, 17, 18)], Cdc61-119
(residues 1-119, a CDK4 substrate that contains an RxLF docking sequence)
(13),  and  p107949-1068 (residues  949-1068,  which  lacks  any  known  docking
sequence).  In  the  case  of  all  four  substrates,  the  KM of  ATP  for  the
K4D1/phosp27 trimer was reduced compared to that of K4D1/- and was more
similar to the KM of CDK2 and that of most serine/threonine kinases (16).  This
decrease in KM, which we also observed for CDK6-CycD1 but not for CDK2-
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CycA (Fig.  S5),  is  consistent  with  our  structural  results  that  p27 binding
induces an N-lobe conformation in CDK4 that supports ATP coordination.  We
note that although we observed activity from reconstituted phosp27-CDK6-
CycD1 trimers in vitro, it is unclear whether these complexes exist in cycling
cells (43).
In  the  activity  assays,  phosp27  also  had  an  inhibitory  effect  that  is
specific for substrates containing a CDK docking sequence. When assaying
the K4D1/- dimer, the ATP Vmax and the Rb substrate kcat/KM both decreased
upon deletion of the docking sequence in Rb (compare Rb771-928 to Rb771-874),
supporting the importance of docking in dimer phosphorylation of Rb (Fig.
3G and S4B)  (17, 18).  The ATP Vmax decreased upon addition of  phosp27
when  assaying  Rb771-928 (13-fold  decrease)  and  Cdc61-119 (4-fold  decrease),
which both contain docking sequences (Fig. 3G). In contrast, the ATP Vmax
only modestly decreased for p107949-1068 and for Rb771-874, which lack docking
sequences. The Rb771-928 substrate kcat/KM but not the Rb771-874 substrate kcat/KM
decreased upon addition of p27 (Fig. S4B), and the kinetics of the trimer
activity toward both Rb substrates were similar (Fig. 3G). These observations
indicate that even in the active complex, p27 inhibits CDK4 activity toward
some substrates by occluding the docking site in CycD (Fig. 2A). 
Structural  mechanism  of  p27-CDK4-CycD  activation  by  tyrosine
phosphorylation
We  solved  the  structure  of  a  phosp27-CDK4-CycD1  complex  to
determine how tyrosine phosphorylation relieves p27 inhibition (Table S1).
Y74 was in a similar position to that in the unphosphorylated trimer, but there
was clear electron density for the phosphate (Fig. 4, A and B, and Fig. S6).
Y74 is part of an aromatic cluster in p27 D2 that binds the CDK4 N-lobe. The
structural  data  predict  that  Y74  phosphorylation  would  weaken  this
association by destabilizing the hydrophobic interface between Y74 and the
N-lobe of CDK4 (Fig. 4, A and B). In p21, a phenylalanine (F62) is in the
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position of  Y74 in p27 such that the p21 D2 domain would remain bound
without the addition of a phosphate (Fig. 1C and Fig. 4C). 
In  a  structure  we  solved  of  the  trimer  containing  p27  with
phosphomimetics  (Table  S1),  temperature  B-factors  were  ~10  to  20  Å2
higher for sidechains in the aromatic cluster in D2 and the electron density
was weaker around W60 and E74 (Fig. S6). The higher B-factors and weaker
density are consistent with lower D2 occupancy and higher disorder. Deletion
of  the  D2  domain  from  p27  or  mutation  of  the  tyrosines  to  glutamate
phosphomimetics  generated a trimer complex that phosphorylated Rb771-928
(Fig.  4D and Fig.  S7).  Solution  studies  with  p27  binding  to  CDK2-CycA
demonstrate  that  phosphorylation  of  Y74  results  in  loss  of  interactions
between the D2 domain of p27 and the N-lobe of CycA (44). Together these
results  support  a  model  in  which  phosphorylation  or  phosphomimetics
weaken  the  affinity  of  the  D2  domain  for  CDK4  N-lobe,  allowing  for  the
formation of the Gly-loop and activation of the kinase. The activation segment
was not homogeneously phosphorylated in our structure (Fig. S2B), so we
cannot  rule  out  that  activation  segment phosphorylation  and the  ultimate
repositioning of the C-helix also plays a role in removing the D2 domain from
the N-lobe. 
Y88  and  Y89  were  disordered  in  all  the  p27-CDK4-CycD1  crystal
structures,  and  the  CDK4  trimer  assembled  with  p27  containing  a
phosphomimetic at Y74 had similar though slightly less activity to that of the
enzyme  assembled  with  phosphomimetics  at  all  the  tyrosines  (Fig.  4D).
Thus, Y74 phosphorylation appeared to be nearly sufficient for p27 activation
of  CDK4,  although  the  data  indicate  that  there  may  have  been  some
contribution  from  Y88/Y89  phosphomimetics  in  the  p27  triple  glutamate
mutant (Fig. 4D). This mechanism for turning off p27 inhibition is different
from the mechanism in CDK2, in which phosphorylation of p27 Y88 and Y89
are necessary for ejection of a p27 310 helix from the catalytic site (Fig. S1C)
(45).  These phosphorylation sites in p27 and the corresponding site in p21
(Y77) are located in a sequence that remains disordered upon CDK4 binding
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(Fig. 1C),  which is consistent with their  weaker role in the mechanism of
CDK4 activation. The more important role of the Y74 phosphorylation site also
explains  the  observed  poor  activity  of  Brk-phosphorylated  p21  complexes
(Fig. 3E), as p21 lacks a tyrosine at the equivalent position of Y74 in p27
(Fig. 1C and Fig. 4C). We conclude that while p21, like p27, primes CDK4
for  catalysis  by  releasing  the  activation  segment,  p21  tyrosine
phosphorylation  does  not  relieve  D2  inhibition,  and  the  complex  remains
mostly inhibited.
p27-CDK4-CycD1 complexes are insensitive to CDK4/6-specific inhibitors
The structural changes in the kinase N-lobe that are induced by p27
binding  indicate  that  palbociclib-type  inhibitors  should  have  poor  potency
toward active CDK4 trimer complexes (Fig. 5A). The “gatekeeper” residue
Phe93 in 5 and also Ala33 in 3 are rotated away from making contacts with
the  C5-methyl  and  C6-acetyl  groups  in  the  pyridopyrimidine  scaffold  of
palbociclib  (46,  47).  We  tested  the  effects  of  palbociclib,  ribociclib,  and
abemaciclib on activity of the reconstituted CDK4 enzyme complexes (Fig.
5B and Fig. S8A). All three compounds inhibited Rb771-928 phosphorylation by
CDK4-CycD1 dimer (K4D1/-) as expected; however, the active phosp27-CDK4-
CycD1 trimer (K4D1/phosp27)  was relatively  insensitive to the drugs,  with
apparent inhibition constants ~10  M or higher. We measured the binding
affinity of palbociclib for CDK4 complexes by isothermal titration calorimetry
(ITC).  The  drug  only  bound  CDK4  monomer  and  K4D1/-  dimer  tightly.
Consistent with our structural and kinetic data, we detected no affinity for
K4D1/phosp27 trimer (Fig. 5C and Fig. S8B). We also measured binding of
p27 to CDK4 monomer and found no affinity if the enzyme was first saturated
with  palbociclib  (Fig.  5C  and  Fig.  S8C).  These  data  demonstrate  that
binding of p27 and palbociclib to CDK4 are mutually exclusive. 
Palbociclib does not inhibit endogenous CDK4 activity
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We tested whether the activity of endogenous cellular CDK4 complexes
is  inhibited  by  palbociclib.  We  immunoprecipitated  p27  complexes  from
MCF7,  MDA-MB-231,  and T98G cells.  MCF7 and MDA-MB-231 cells  are Rb-
positive and palbociclib-sensitive breast cancer cells that differ in estrogen
receptor (ER) status (46). T98G cells are Rb (+) and ER (-) glioma cells that
are  relatively  less  sensitive  to  palbociclib  (see  below,  Fig.  8A).  The
immunoprecipitates  phosphorylated  purified  Rb771-928  in  the  32P-ATP  assay;
however,  the activity was insensitive to palbociclib  that was added to the
kinase reactions  (Fig.  5D).  We considered that  this  palbociclib-insensitive
activity might be from CDK2. While it is thought that cellular CDK2 complexes
with  p27  are  not  active  (32),  we  found  that  reconstituted  K2A/phosp27
complexes  phosphorylated  Rb  (Fig. S5C).  However,  the  p27
immunoprecipitate  activity  was  also  not  inhibited  by  the  CDK2  inhibitor
dinaciclib,  and  therefore  the  immunoprecipitate  likely  contained  a  CDK4
activity and not a CDK2 activity (Fig. S9). 
To test the entire cellular pool of CDK4 activity, we immunoprecipitated
CDK4 from the same cell lines using an antiserum raised against the CDK4 C-
terminus, which contains a sequence distinct from CDK2 (48). Palbociclib also
poorly  inhibited  the  immunoprecipitated  CDK4  kinase  activity  (Fig.  5E),
which  is  consistent  with  previous  observations  that  CDK4  activity  mostly
arises from trimer complexes  (25, 31-37) and our observation that trimer is
insensitive to drug (Fig. 5B). 
An ATP-site occupancy probe targets CDK4 monomers in cells
To  examine  the  association  of  an  inhibitor  with  endogenous  CDK4
complexes, we treated MCF7 and MDA-MB-231 cells with the covalent ATP-
site occupancy probe XO44 (49).  XO44 labeled both CDK4 and CDK2 in these
cells and could be detected by a gel shift upon coupling to an analysis probe
(Fig. 6A and Fig. S10, A and B). While XO44 labeled most CDK2 and the
mitotic kinase Aurora B (Fig. S10A), it labeled only ~40 to 60% of CDK4 even
at high concentrations, indicating that a resistant population of the protein
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exists. CDK4 labeling in cells was inhibited by palbociclib (Fig. 6B and Fig.
S10C),  demonstrating  that  XO44  and  palbociclib  bind  the  ATP  site
competitively and that the population of CDK4 that is targeted by XO44 is
also targeted by palbociclib-type inhibitors.  XO44 labeled recombinant CDK4
efficiently in dimer complexes but not in unphosphorylated or phosphorylated
trimer complexes (Fig. 6C). 
We treated cells with XO44 and palbociclib and fractionated the lysates
with size-exclusion chromatography (Fig. 6D and S10D). We observed CDK4
in  high-molecular-size  fractions  co-migrating  with  Hsp90  and  Cdc37  (e.g.
fractions 5 and 6), in mid-size fractions with CycD1 and p27 (fractions 9 and
10), and in low-size fractions that likely contain monomers (fractions 15 and
16)  (34, 36).  Consistent with ATP-competitive probes sequestering obligate
Hsp90-client  kinases from the chaperone system  (50,  51),  we observed a
reduction  in  the  abundance  of  large-sized,  putatively  Hsp90/Cdc37-bound
CDK4 in extracts from XO44- and palbociclib-treated cells. We also detected
greater quantities of CDK4 in small-sized monomer fractions upon treatment
with  either  compound,  and  only  the  CDK4  population  observed  in  these
fractions was labeled with XO44 (Fig. 6D, fractions 15 and 16, XO-44 + click).
Considering that CDK4 inhibitors do not associate with CDK4 bound by INK
proteins  (52),  we  propose  that  the  tested  inhibitors  primarily  bind  CDK4
monomers  in  cells  and  increase  the  abundance  of  the  inactive  monomer
population.
 We synthesized a palbociclib analog linked to biotin, and we used it to
precipitate CDK4/6 from cell extracts to determine which proteins exist in the
complexes targeted by palbociclib-type inhibitors (Fig. 7A). Consistent with
our  activity  and  ITC  binding  assays,  the  palbociclib-biotin  precipitated
recombinant CDK4-CycD1 dimer but not recombinant p27-CDK4-CycD1 trimer
(Fig.  7B).  Strikingly,  in  breast  cancer  cell  lysates,  the  palbociclib-biotin
strongly precipitated CDK4 and CDK6, but did not precipitate any detectable
p21 or p27 (Fig. 7, C and D). This observation demonstrates further that the
drug does not bind trimer complexes with p21 and p27 in these cells. A faint
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band reproducibly appeared in the CycD1 blot, indicating that there may be
some small population of dimer complexes targeted by the drug. However,
we conclude that monomer CDK4 and CDK6 are the predominant targets of
palbociclib in these cells.
Palbociclib-induced cell-cycle arrest coincides with loss of CDK2 and not
CDK4 activity
We treated cells with palbociclib for 48 hrs, which, similar to previous
descriptions, lead to strong arrest of the breast cancer cells and to weaker
arrest of T98G cells as determined by EdU incorporation and propidium iodide
staining  (53,  54) (Fig.  8A and Fig.  S11).  Endogenous  CDK4 and CycD1
complexes  retained  kinase  activity  despite  the  cells  arresting  with  drug
treatment (Fig. 8B and S12A).  This  similar  activity  in  palbociclib-treated
cells  was  observed  despite  increased  levels  of  CycD1 (Fig.  8C and Fig.
S12B)  (53). In contrast, CDK4 complexes immunoprecipitated from serum-
starved NIH/3T3 cells lack Rb-directed kinase activity (Fig. S12C), and the
lack of  activity  coincides with reduced CycD1 levels.  In  the cycling breast
cancer cells tested, we did not observe palbociclib inhibiting CDK4- or CycD1-
associated kinase activity,  which is consistent with the lack of  susceptible
dimer complexes that could be detected in their lysates (Fig. 6D and Fig. 7,
C and D).
Unlike CDK4 complexes, CDK2 complexes immunoprecipitated from the
breast  cancer  cells  had  diminished  activity  following  48-hr  palbociclib
treatment  (Fig.  8B).  CDK2  inhibition  at  this  drug  concentration  is  likely
indirect (5, 46), resulting at least in part from lower levels of CycA (Fig. 8C)
(53).  We also observed evidence for an increase in p21 but not p27 in CDK2-
CycE complexes  (Fig. 8, C and D and Fig. S12, D and E). In reciprocal co-
immunoprecipitation  experiments,  additional  p21-CycE  association  was
detected after 48 hrs. We could not detect p27 in the CycE1 IP either without
or with palbociclib treatment, so we cannot determine whether p27 also plays
a  role  in  down-regulating  the  CDK2-CycE  activity.  We  conclude  that
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palbociclib treatment indirectly leads to CDK2 inhibition and that this CDK2
inhibition, and not CDK4 inhibition, correlates with cell-cycle arrest. 
Discussion
CIP/KIP proteins were first characterized as CDK inhibitors, particularly as
potent  inhibitors  of  CDK2-CycA/E  (25,  55-59).  In  contrast,  other  evidence
implicated  non-inhibitory  roles  for  p21  and  p27  in  mediating  CDK4-CycD
function,  including  complex  assembly  and  nuclear  localization  (31,  37).
Moreover, the observations that active CDK4-CycD tolerated the presence of
p27 and that Rb-directed kinase activity in cells contained p27 led to models
that CDK4-CycD may titrate inhibitory p27 away from CDK2 (25, 33, 37, 60).
Our data demonstrate that p27 is not merely a non-inhibitor,  but it in fact
allosterically  activates  CDK4-CycD,  remodeling  the  kinase  to  increase  the
catalytic efficiency of ATP processing. Our structural data demonstrate that
this  effect is  specific to CDK4 (vs.  CDK2) and is primarily  induced by Y74
phosphorylation in p27.  While p21 also acts as an assembly factor for active
CDK4-CycD1 (31), p21 contains a phenylalanine at the equivalent position as
Y74 (Fig. 1C and 4C), and p21 trimer complexes cannot be activated by D2
displacement as in p27. As a result,  phosphorylated p21 trimer complexes
have relatively less activity than phosphorylated p27 complexes.
The catalytic  efficiency of  the phosp27-CDK4-CycD1 trimer  was greater
than  the  catalytic  efficiency  of  the  dimer  for  most  of  the  substrates  we
investigated (Fig. 3G). The requirement of p27 for efficient phosphorylation
may explain why, relative to CDK2 for example, fewer cell-cycle substrates
have been identified for CDK4/6 and why it has been thought that Rb is a
preferred CDK4/6 substrate (12, 14, 15, 17, 18). Additional CDK4/6 substrates
have been identified more recently  (13, 61, 62), and it will be important to
explore the role of p27 in their regulation by CDK4/6 phosphorylation. Our
observation that the CDK4-CycD1 dimer catalytic efficiency was dependent
on  the  last  ~50 amino  acids  of  Rb  is  consistent  with  reports  of  a  CDK4
docking site in the Rb C-terminal domain (17, 18).  Docking allows Rb to more
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tightly  associate  with  the  dimer  and  be  phosphorylated  even  when  ATP
affinity is so low.  In contrast, we observed that the trimer activity did not
depend  on  a  substrate  docking  sequence,  suggesting  that  a  role  of  p27
activation  may  be  to  broaden  CDK4  substrate  specificity.  Our  data  also
implicate a competitive association between Rb and p27 for CDK4-CycD and
indicate that p27 still functions to temper Rb-directed CDK4 activity even in
the context of active trimer complexes. 
CDK4/6-specific inhibitors were developed through optimizing potency and
selectivity toward CDK4-CycD dimer, despite evidence that the physiological
complex contains CIP or KIP family inhibitors such as p27 (25, 31-37, 46). Our
data demonstrate that active recombinant CDK4 complexes containing p27
are not sensitive to these inhibitors and that palbociclib does not associate
with active endogenous p27 trimer complexes. Moreover, we did not detect
inhibition of CDK4 activity in drug-arrested breast cancer cells, and we did not
robustly  detect  CDK4-CycD1  dimer  complexes  in  cell  lysates.  Still,  we
recognize that dimer inhibition may occur in some contexts and that some
small population of dimer may be targeted even in the breast cancer cells
tested here. In light of the differences between dimer and trimer response to
CDK4/6 palbociclib-type inhibitors in vitro, it will be important to explore how
the balance of dimer and trimer complexes may influence sensitivity to drugs
in cells or in vivo.
Our  data implicate an additional  mechanism toward cell-cycle  arrest  in
which  palbociclib  associates  with  CDK4  monomer  instead  of  binding  and
inhibiting CDK4 dimer or trimer activity.  One outcome is that the population
of  CDK4 monomer  increases,  and  it  is  possible  that  this  CDK4-palbociclib
complex is recognized and induces a response, such as the decrease in CycA
abundance (53) or an increase of p21 in CDK2-CycE complexes. Both of these
outcomes correlate with our observed lower CDK2 activity. A reported CDK4/6
degrader  drug  is  not  as  effective  as  palbociclib  in  inhibiting  Rb
phosphorylation  (63),  and,  a  recent  study  finds  that  cells  expressing  a
catalytically inactive CDK4 are arrested when treated with palbociclib  (64).
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These  results  perhaps  reflect  the  fact  that  palbociclib-induced  cell-cycle
arrest does not require inhibition of  CDK4 activity but alternatively results
from indirect  inhibition  of  CDK2.  This  indirect  role  of  CDK4 in  modulating
CDK2 activity is consistent with observations that CDK4-CycD expression can
activate CDK2 through sequestration of p27 and without the requirement of
CDK4 catalytic activity (25, 59).
We note the similarity of this mechanism of palbociclib inhibition with that
of  the p16-INK family  of  CDK4 protein  inhibitors,  which sequester  inactive
monomer CDK4 (Fig. 8E). The ability of palbociclib to mimic p16 may in part
explain  why cells  lacking  p16 are  often  most  sensitive  to  palbociclib-type
inhibitors  (53,  54,  65,  66).  We suggest  that,  similarly  to  the  downstream
effects of p16, accumulation of CDK4 monomer upon palbociclib treatment
indirectly  lowers  CDK2 activity,  potentially  through the shuttling of  p21 to
CDK2  complexes  (25,  36,  67,  68).  In  cycling  cells,  this  drug-induced
reorganization  of  CDK  complexes  may  occur  when  p21  is  re-synthesized
following its degradation before S phase and/or when CycD1 is low in S phase
and would lead to cell-cycle arrest (69). The targeting of an inactive kinase,
rather than inhibition of assembled kinase activity, may apply to other kinase
therapeutic targets as well  (70), and we note that Gleevec similarly inhibits
an inactive confirmation of the Abl kinase (71).
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Materials and Methods:
Recombinant protein expression
Full-length human CDK4, CDK6, cycD1, p21, p27, and Brk were expressed
and purified from Sf9 cells. CDK4, CDK6, p21, p27, and Brk were expressed as
GST  fusion  proteins.  CycD1  was  co-expressed  with  other  components
untagged or, where indicated, with a Strep tag. Lysates were first purified by
GS4B affinity chromatography. Proteins were then eluted from the resin and
subject to Source 15Q (GE Healthcare) anion exchange chromatography. The
elution fraction was then subjected to TEV protease cleavage overnight in 25
mM Tris pH 8.0, 200 mM NaCl, 1 mM DTT, 0.5 mM EDTA. The protein was then
passed over GS4B affinity resin again to remove free GST, concentrated, and
stored in a buffer containing 20 mM Tris pH 8.0, 200 mM NaCl, 1 mM DTT, and
20% glycerol. CDK2-CycA was expressed in E. coli and purified as previously
described (72).
Phosphorylation of p21 and p27
Recombinant p21 and p27 were expressed as a GST fusion in  E. coli and
purified as described above. Purified proteins were treated with 10% GST-Brk
(by mass) in a buffer containing 50 mM Tris pH 8.0, 150 mM NaCl, 1 mM DTT,
10  mM  MgCl2 and  1  mM  ATP  and  incubated  at  4°C  for  24  hours.  The
phosphorylated p21 or p27 were purified by passing through GS4B affinity
resin  and eluted from a Superdex 75  column (GE Healthcare)  in  a  buffer
containing 25 mM Tris pH 8.0, 100 mM NaCl, and 1 mM DTT. The extent of
phosphorylation was confirmed using electrospray mass spectrometry on a
SCIEX X500 QTOF spectrometer. 
Crystallization,  data  collection,  structure  determination,  and  model
refinement
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For crystallization, human CDK4 (residues 1-303, (ΔG45-G47, G43E, G44E),
truncated cycD1 (16-267), p27 kinase-inhibitory domain (p27KID; 25-93), and
the p21 kinase-inhibitory domain (p21KID; 14-81) were prepared as described
above. The CDK4 contains mutations in a glycine-rich sequence that mimic
CDK6 and were required for  crystallization  (10,  11).  The CDK4 complexes
were prepared for crystallization by elution from a Superdex 200 column (GE
Healthcare) in a buffer containing 10 mM Tris pH 8.0, 100 mM NaCl, and 1
mM DTT. The p27-CDK4-CycD1, p27(3E)-CDK4-CycD1, and p21-CDK4-CycD1
complexes  were  crystallized  from  an  10  mg/mL  solution  by  microbatch
method under Al’s oil at 22°C. Rods formed after three days in 100 mM Tris,
10% PEG 8000, and 200 mM MgCl2, pH 7.0. Crystals were cryo-protected in
reservoir solution supplemented with 25% glycerol and cryo-cooled in liquid
nitrogen.
 The  phosp27-CDK4-CycD1  complex  was  prepared  for  crystallization  by
mixing  3:1  molar  ratio  of  phosphorylated  p27  and  CDK4-CycD1  dimer
followed by elution from a Superdex 200 column in a buffer containing 10 mM
Tris, 100 mM NaCl, and 1 mM DTT, pH 8.0. The complex was crystallized from
an 10 mg/mL solution by sitting drop vapor diffusion method at 22°C. Rods
formed after three days in 100 mM Tris, 17% PEG 3350, 100 mM CaCl2 and 10
mM  MgCl2 pH  7.0.  Crystals  were  cryo-cooled  in  the  reservoir  solution
supplemented with 25% glycerol.
Data  were  collected  at  the  Advanced  Light  Source,  Laurence  Berkeley
National Laboratory at beamline 8.3.1. Diffraction spots were integrated using
MOSFLM  (73),  and data were merged and scaled using Scala in the CCP4
software package (74, 75). The structure of the p27-CDK4-CycD1 trimer was
first determined by molecular replacement using Phaser and the CDK4-CycD1
dimer as a search model (PDB ID: 2W9F) (76). A model for p27 was then built
into the extra electron density with Coot (77), and the model was refined with
Phenix  (78).  Models  for  the  CDK4-CycD1  trimer  complexes  containing
phosp27,  p27(3E),  or  p21  were  then  built  and  refined  starting  from  the
unphosphorylated p27 structure.
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Western blots and antibodies
Details on the antibodies used and the procedures for Western blotting can
be found in the Supplementary Materials.
Kinase assays 
Recombinant CDK4 (0.5 μM), CDK2 (0.5 μM), or CDK6 (1 μM) complexes
were mixed with substrate (30 μM) in a kinase buffer containing 25 mM Tris
pH 8.0, 200 mM NaCl, 10 mM MgCl2, 1 mM DTT, 250 μM ATP (or as indicated),
and 100 μCi of  32P-γ-ATP. Substrate was diluted into the reaction buffer, and
the reaction was initiated by addition of ATP. Reactions were quenched after
30  min by  addition  of  SDS-PAGE  loading  buffer.  Independent  time-course
experiments  confirmed  that  phosphate  addition  is  still  linear  with  time
beyond  45 min  using  our  experimental  conditions.  SDS-PAGE  gels  were
imaged  with  a  Typhoon  scanner  and  bands  quantified  using  the  ImageJ
software package. For each assay, three replicates were performed. We note
that our measured Ki values for the inhibitors on K4D1/- (Fig. 5B and Fig.
S8A) are consistent with our ITC-measured Kd  value for palbociclib (Fig. 5C)
but are higher than IC50 values previously reported (4, 7, 46). We believe the
difference is  due to  the higher  ATP concentration  in  our  assay,  which  we
chose to be closer to the ATP KM for K4D1/-.
For the activity assays using immunoprecipitation of  endogenous CDK4,
CDK2, or p27 complexes, 1 mg of whole-cell extract was immunoprecipitated
with 2 g anti-p27 antibody (SCBT DCS-72), 2 g anti-CDK2 antibody (SCBT D-
12), or 20 uL of CDK4 antiserum to C-terminal peptide (gift of Charles Sherr,
St. Jude Children’s Research Hospital) (48) and 25 L protein A/G PLUS beads
(SCBT) for 2 hr at 4°C. The beads were then washed 3 times with 50 mM Tris
pH  7,  150  mM  NaCl,  1  mM  DTT,  and  5%  glycerol.  The  final  wash  was
performed  in  kinase  buffer  and  the  reaction  was  performed  with  the
recombinant substrate while the enzyme complexes were on the beads.
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For the activity assays using immunoprecipitated CycD1 complexes, MCF7
cells were lysed with lysis buffer containing 50 mM Tris-HCl pH 7.5, 150 mM
NaCl,  0.1%  NP-40,  10  mM  DTT,  10%  glycerol,  1X  Halt  protease  inhibitor
(Thermo Fisher), and 1 mM PMSF. 5 µg of anti-CycD1 (Invitrogen; MA5-12707)
was incubated with 300 µg of the lysate overnight at 4°C. Normal mouse IgG1
(Cell Signaling Technology, 5415) was used as a control. Protein G agarose-
beads were added to each IP samples and incubated up to 4 hour at 4°C.
Protein immunocomplexes were washed 3 times with the lysis buffer and 2
times with kinase reaction buffer (50 mM HEPES-KOH pH 7.5, 20 mM MgCl2 1
mM DTT). Kinase reactions were carried out in 100 µl of kinase buffer in the
presence of 2 mM ATP and 0.5 µg of recombinant Rb C-terminal domain as
substrate by gently shaking at room temperature up to 1 hour. The resulting
phosphorylated Rb protein was detected by western blotting using anti-p-Rb
(S780) antibody (Cell Signaling Technology, 9307L).
Activity assays with immunoprecipitated CycE1 complexes were performed
similarly, but the lysis buffer contained 50 mM HEPES-KOH pH 7.5, 150 mM
NaCl,  1  mM EDTA,  1mM DTT,  0.1% Tween-20,  1X  Halt  protease  inhibitor
(Thermo Fisher), and 1 mM PMSF. Immunoprecipitation was performed with
an anti-CycE1 antibody (Santa Cruz Biotechnology; SC-377100) as described
for CycD1. The kinase reactions were performed in 100 µl of kinase buffer (40
mM  Tris-HCl  pH  8.0,  20  mM  MgCl2,  0.1  mg/mL  BSA,  50  µM  DTT)  in  the
presence  of  2  mM ATP  and  0.5  µg  of  Rb  protein  as  substrate  by  gently
shaking at room temperature up to 1 hour. The resulting phosphorylated Rb
protein  was  detected  by  western  blotting  using  anti-p-Rb  (S807/S811)
antibody (Cell Signaling Technology, 8516S).
XO44 labeling assays
XO44 labeling was carried  out  as previously  described  (49) with some
modifications. Live adherent cells were labeled by incubation with 2 µM XO44
at 37˚C for 30 min. Cells grown in 15-cm dish format to be analyzed by gel
filtration  were  harvested  as  described  below.  Cells  grown  in  6-well  plate
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format (seeded at 500,000 cells/well and allowed to recover for ~20 hr) to be
analyzed by western blot were then washed twice with cold PBS, perturbed
and lysed in place with 80 µL lysis buffer containing 100 mM HEPES pH 7.5,
150 mM NaCl, 0.1% NP-40, 1x cOmplete EDTA-free protease inhibitor cocktail
and 1x PhosSTOP phosphatase inhibitor cocktail (both Roche). Lysates were
clarified by centrifuging at 20,000 g for 20 min, then normalized to 2.5 mg/mL
protein concentration using the Pierce Rapid Gold BCA assay (Thermo). 20.75
µL  of  lysate  was  treated  with  4.25  µL  of  a  master  mix  to  give  final
concentrations of 1% SDS, 50 µM TAMRA-azide (in DMSO), 1 mM TCEP, 100
µM  TBTA  (in  1:4  DMSO:t-butyl  alcohol)  and  1  mM  CuSO4.  The  resulting
mixture was incubated at room temperature for 1 hr before being quenched
with 5 µL 6X SDS loading buffer and analyzed by western blot as described
above. The TAMRA dye was used to add mass to XO44-labelled CDK4, so the
XO44 modification is observable as a gel shift by using SDS-PAGE.
Gel filtration assay
Gel filtration assays on crude cell lysates were performed as previously
described with modifications  (36). Cells were seeded on 15-cm dishes at 10
million cells per dish and allowed to recover for ~20 hr before treatment with
compounds  as  indicated and harvesting by  washing with  PBS followed by
trypsinizing, pelleting and two further washes with cold PBS. Pellets of ~25
million cells were lysed in buffer containing 50 mM Tris pH 7.5, 150 mM NaCl,
1%  NP-40,  10%  glycerol,  1  mM  EDTA  plus  cOmplete  EDTA-free  protease
inhibitor cocktail  (Roche) on ice for 20 min. Lysates were then clarified by
centrifuging  at  18,000  x  g  for  2x15  min.  500  µL  (5  mg)  of  lysate  was
incubated with DNase I (NEB, 1 unit/mg lysate) in 1x DNase 1 reaction buffer
(NEB) for 20 min on ice and briefly clarified again by centrifuging for 5 min.
Samples were then loaded on a Superdex200 Increase 10/300 GL column pre-
equilibrated in 50 mM HEPES pH 7.5, 150 mM NaCl, 1% NP-40, 10% glycerol.
The column was eluted for 1.25 column volumes at 0.35 mL/min and 0.5-mL
fractions were collected starting at 5 mL. Fractions 10-26 were analyzed by
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western  blot  as  described above.  Samples  of  fractions  from XO44-treated
cells were used in click reactions as described above. To benchmark purified
protein complexes, 0.8 µg of p27-CDK4-CycD1 trimer was diluted in 500 µL
HEPES  buffer  for  loading.  Gel  filtration  and  western  blot  analysis  were
performed as described above.
LC-MS analysis of CDK4 covalent labeling
Recombinant  purified  protein  complexes  (1  M)  were  suspended  in  a
buffer containing 20 mM HEPES, 150 mM NaCl, and 1 mM MgCl2, pH 7.5, and
treated with XO44 (10 μM) or DMSO (1 % (v/v) DMSO final). After 30 min at
room  temperature,  reactions  were  stopped  by  the  addition  of  10%  (v/v)
formic acid to a final concentration of 2% (v/v) formic acid. The extent of
covalent labeling was assessed by LC-MS (Waters Xevo G2-XS QTof, ACQUITY
UPLC  Protein  BEH  C4  Column,  300Å,  1.7  µm,  2.1  mm  X  50  mm).
Deconvolution  of  multiply  charged  ions  was  performed  using  Waters
MassLynx software (version 4.1). 
Palbociclib-biotin
Details of the synthesis and characterization of palbo-biotin can be found
in the Supplementary Materials.
For  palbo-biotin  precipitations,  100  M  palbo-biotin  was  first  incubated
with streptactin beads in PBS for 30 minutes at room temperature. The beads
were then washed 3X with PBS and resuspended in 1 mg of cell extract in 50
mM HEPES pH 7.0, 150 mM NaCl, 0.1% Tween-20, 1 mM DTT, 5% glycerol, 1x
cOmplete EDTA-free protease inhibitor cocktail  and incubated at 4°C for 2
hours.  Complexes  bound  to  streptactin  beads  were  eluted  using  2X  SDS
buffer and subjected to immunoblot  analysis.  For  recombinant  protein  the
same protocol was followed except 2  g recombinant protein was added to
the beads in IP buffer with 1% BSA. 10 M excess free palbociclib was added
to the extract or purified proteins where indicated.
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Isothermal Titration Calorimetry
Equilibrium dissociation constants were obtained using a Micro Cal VP-ITC at
15°C.  For  drug  binding  experiments,  40  M  purified  CDK4-CycD1,
phosp27(p27KID; 25-93)-CDK4-CycD1, and GST-CDK4 were dialyzed overnight
in a buffer containing 25 mM Tris  pH 8.0,  200 mM NaCl,  and 5 mM BME.
Proteins were titrated with 0.5 mM palbociclib dissolved in the same buffer.
For measurement of p27 (p27KID; 25-93) binding to GST-CDK4, proteins were
eluted in separate runs from a Superdex 200 column equilibrated in a buffer
containing 25 mM Tris pH 8.0, 200 mM NaCl, and 5 mM BME. 250 M p27 was
titrated  into  40  M  GST-CDK4  in  the  absence  and  presence  of  M
palbociclib.
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Figure legends:
Fig.  1:  Structures  of  the  p27-CDK4-CycD1  and  p21-CDK4-CycD1
complexes.  (A)  Overall  structure  of  p27-CDK4-CycD1.  p27  (green)  binds
CycD1 (cyan) with its D1 domain and CDK4 (gold) with its D2 domain.  (B)
Structure of p21-CDK4-CycD1. p21 (magenta) adopts a similar fold to p27,
bridging CDK4 (gold) and CycD1 (cyan). (C) Sequence alignment of p27 and
p21.  Asterisks represent residues directly  interacting with CDK4 or CycD1.
The  known  tyrosine  phosphorylation  sites  are  noted.  Secondary  structure
observed  in  the  crystal  is  indicated  above  the  sequences.  Dashed  lines
indicate  sequences  in  the  crystallized  protein  that  are  not  visible  in  the
electron density, including the C-terminal sequence in p27 that forms a 310
helix when bound to CDK2 (in parentheses).
Fig. 2: p27 and p21 inhibit substrate binding and catalytic activity.
(A) Association between the p27 RxLF motif (green) and the MVRIL cleft in
CycD1 (cyan) competes for substrate docking. (B) The p21 RxLF (magenta)
bound to CycD1 (cyan). (C) Binding of the D2 region in p27 (green) displaces
the β1 strand in the CDK4 N-lobe (gold), disrupting the ATP-binding site. The
structure shown in grey for comparison, including the ATP, is from CDK2 in
the active CDK2-CycA dimer. The CDK4 β1 strand and following Gly-loop are
not  visible  in  the p27-CDK4-CycD1 trimer  structure,  indicating  they  are
disordered. The C-helix remains in an inactive conformation in the CDK4-p27
structure. (D) Comparison of binding of p27 to CDK2 (p27 in grey) and to
CDK4 (p27 in green, CDK4 in gold).  The 310 helix in p27 that binds the CDK2
ATP-site  is  not  visible  and  likely  remains  disordered  upon  CDK4  binding.
Tyrosine phosphorylation sites are shown.
Fig.  3:  p27  induces  structural  changes  that  promote  ATP
coordination and processing. (A-D) Structural alignment of CDK4-CycD1
with  p27  (gold-cyan)  and  without  p27  (red,  PDB  code:  2W96)  reveals
movement of both the CDK4 N-lobe and CycD1 domains relative to the CDK4
C-lobe. (E) Phosphorylation of purified Rb771-928 with 32P-ATP and the indicated
dimer  (K4D1/-)  or  trimer  complex.  (F-G) Steady  state  kinase  assays
measuring effects of ATP concentration on initial reaction rate, measured by
incorporation  of  32P-ATP.  Reactions  include  CDK4 dimer  (K4D1/-)  or  active
trimer (K4D1/phosp27) and the indicated substrate.
Fig.  4:  Y74  phosphorylation  disrupts  the  p27  D2-CDK4  interface.
Comparison of CDK4-CycD1 structures with  (A) unphosphorylated p27,  (B)
phosphorylated  p27,  and  (C) p21.  (D) 32P-ATP  phosphorylation  of  Rb771-928
using K4D1 dimer or trimer enzymes assembled with the indicted p27 kinase
inhibitory domain construct (residues 25-93).  3E contains three glutamate
phosphomimetics at Y74, Y88 and Y89. ΔD2 contains p27 residues 25-60, and
therefore lacks the D2 CDK4-binding domain
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Fig.  5:  Palbociclib  does  not  bind  and  poorly  inhibits  purified  and
endogenous CDK4 trimer complexes.  (A)  K4D1 dimer (PDB ID:  2W96)
and the phosp27-K4D1 trimer structures were aligned with palbociclib-bound
CDK6 (PDB ID: 2EUF, not shown) to model the position and interactions of the
drug  when  bound  to  CDK4. (B) 32P-ATP  phosphorylation  of  Rb771-928 using
CDK4-CycD1  dimer  (K4D1/-)  and  phosp27-CDK4-CycD1  trimer
(K4D1/phosp27) enzymes in the absence (left most lane in each titration) and
presence  of  increasing  inhibitor  concentrations  (see  Fig.  S8A for
quantification).  Each  drug  is  dosed  from  0.2  M  to  16.2  M  in  3-fold
increments. (C) ITC affinities for palbociclib (left) or p27 (right) titrated into
the indicated enzyme. (D) The indicated cell lysates were immunoprecipitated
with control or with p27 antibody, and the activity of the immunoprecipitate
was used to phosphorylate Rb771-928 with 32P-ATP in the absence or presence of
palbociclib. Reactions with the indicated recombinant dimer (K4D1/-) or trimer
(K4D1/phosp27) enzymes are shown for comparison in the first four lanes. (E)
As in panel D, except lysates were precipitated with antiserum raised against
a CDK4 C-terminal peptide.
Fig. 6: The ATP-site occupancy probe XO44 labels monomer CDK4 in
MCF7  cells.   (A) Labeling  of  endogenous  CDK4  and  CDK2  by  the
promiscuous  covalent  ATP-site  probe  XO44.  MCF7 cells  were  treated  with
DMSO vehicle or XO44 at the indicated concentrations for 30 min. Lysates
were subjected to click reaction with TAMRA–azide to visualize XO44 labeling
of proteins by gel mobility shift. (B) Palbociclib competes with XO44 for CDK4
binding but not CDK2 binding. Experiment performed as in panel A, but cells
were pretreated for 60 mins with DMSO, a non-clickable analog of XO44 (XO-
nc),  or  with  increasing  concentrations  of  palbociclib. (C)  XO44  efficiently
labels purified recombinant CDK4-CycD1 dimer but not trimer complexes with
p21  or  p27  as  determined  by  electrospray  ionization  mass  spectrometry.
Protein  complexes  were  treated  with  DMSO  or  XO44.  Average  percent
labeling was determined for three replicates with standard deviation shown
as error bars. (D) Asynchronous MCF7 cells were treated with DMSO, XO44 (2
μM, 30 min) or palbociclib (500 nM, 4 hr), and lysates were fractionated using
Superdex200 size-exclusion chromatography. XO44 labeling was monitored
by  gel  mobility  shift  after  click  reaction  with  TAMRA–N3 (“XO44  click”).
Normalized quantification of band signals from the western blots using the
indicated  antibody  are  shown.  A  benchmark  chromatography  experiment
using the  recombinant  protein  complex is  displayed at  the bottom of  the
panel. See Fig. S10 for data using MDA-MB-231 cells. 
Fig. 7: Palbociclib directly targets CDK4/6 monomer in cell lysate. (A)
Chemical  structure  of  palbociclib-biotin  synthesized  here.  (B)  Palbociclib-
biotin  precipitated  purified  recombinant  CDK4-CycD1  dimer,  but  not  p27-
CDK4-CycD1 trimer. (C and D) MCF7 or MDA-MB-231 cell lysates were used
in a precipitation reaction with palbociclib-biotin. A CycD1 antibody was also
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used to precipitate CDK4/6 from cell  lysates  to compare the total  pool  of
CycD1 complexes to palbociclib-bound complexes. 
Fig.  8:  Palbociclib  indirectly  leads  to  down-regulation  of  CDK2
through p21. (A) Cell-cycle profiling of the cell lines used in this study upon
treatment with 500 nM palbociclib for 4 or 48 hr or without drug treatment.
Cells  were  assayed  for  5-ethynyl-2-deoxyuridine  (EdU)  incorporation  as  a
marker of S phase at the different time points following drug treatment. The
fraction of cells showing EdU staining is reported. EdU incorporation in cells
that  were  serum  starved  (serum  free)  for  48  hours  is  also  shown  for
comparison. (B) Cells were treated with palbociclib as indicated for 48 hr, and
lysates were immunoprecipitated with CDK4 antiserum or a CDK2 antibody.
Activity of the immunoprecipitated complexes was assayed as in  Fig. 5, D
and  E.  (C)  CycD1-,  p27-,  and  p21-associated  complexes  were
immunoprecipitated from MCF7 cells treated with palbociclib for the indicated
time  and  proteins  were  detected  by  Western  blot.  (D)  CycE1  was
immunoprecipitated from MCF7 cells treated with palbociclib for 48 hrs. (E)
Model for trimer assembly and CDK4 inhibition by palbociclib. Like p16 family
CDK4  inhibitors,  palbociclib  binds  monomer  CDK4  and  indirectly  leads  to
inactive CDK2 complexes. Although not observed in the breast cancer cells
studied here, there may be some contexts in which palbociclib also targets
CDK4 dimers.
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